Tipifarnib (R115777; Zarnestra), the first non-peptidomimetic FTI tested in clinical trials, demonstrated significant tumor inhibition, although it was only partially effective against KRAS-mutant cells (NCT00006199) [114, 130, 131]. This evidence concerns the gene KRAS and neoplasm.